TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03823378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elsubrutinib
Description: Elsubrutinib capsule will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elsubrutinib
Description: Elsubrutinib capsule will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elsubrutinib
Description: Elsubrutinib capsule will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elsubrutinib
Description: Elsubrutinib capsule will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elsubrutinib
Description: Elsubrutinib capsule will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Upadacitinib tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Upadacitinib tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Upadacitinib tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for elsubrutinib
Description: Placebo capsule for elsubrutinib will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for upadacitinib
Description: Upadacitinib placebo tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for upadacitinib
Description: Upadacitinib placebo tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for upadacitinib
Description: Upadacitinib placebo tablet will be administered orally.
Study: NCT01772511

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: All patients entering on this trial will have been enrolled on an oncology clinical trial and are receiving active anti-cancer treatment on that study.
Study: NCT01623986

Intervention type: DEVICE
Intervention: Mespere Venus 1000 System
Description: An adhesive patch (connected to the Mespere Venus 1000 System) is placed on the neck of the subject, to determine if the CVP values displayed by the device correlates with right atrial pressure values obtained by echocardiography(standard clinical practice)

Intervention type: DEVICE
Intervention: Echocardiography machine
Description: Use of ultrasound to estimate right atrial pressure from analyzing inferior vena cava (IVC).
Study: NCT01631019

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile-phone-based Home Exercise Training Program
Description: Patients in the mobile phone group were asked to perform daily endurance exercise training under mobile phone guidance, and the adherence was reported back to the central server. The level of endurance walking was re-assessed and re-adjusted initially on regular clinical visits every four weeks during the first three months. During this period of time, the adherence to protocol was reinforced by telephone from health professionals whenever patients missed one day of their walking training detected by the central system. Patients were asked to continue their exercise program at home at a fixed walking speed, and return to the clinic at 1, 2, 3 and 6 months.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Home Exercise Training Program
Description: all the subjects were assessed by an incremental shuttle walking test (ISWT) (24) for estimation of exercise endurance. Baseline spirometry and body mass index (BMI) were recorded. The adherence and compliance of the home-based exercise training program was assessed by monitoring the frequency of performance and the duration of the endurance walking program recorded on the central system every week. Patients were asked to continue their exercise program at home at a fixed walking speed, and return to the clinic at 1, 2, 3 and 6 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercise Training Program
Description: all the subjects were assessed by an incremental shuttle walking test (ISWT) (24) for estimation of exercise endurance. Baseline spirometry and body mass index (BMI) were recorded. The adherence and compliance of the home-based exercise training program was assessed by monitoring the frequency of performance and the duration of the endurance walking program recorded on the central system every week. Patients were asked to continue their exercise program at home at a fixed walking speed, and return to the clinic at 1, 2, 3 and 6 months.
Study: NCT00522964

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral intervention
Description: The intervention is based on Social Cognitive Theory and principles of Chinese culture and practices. The intervention program includes a one-hour small-group session for eight weeks for children and two 2-hour small-group sessions for parents.
Study: NCT01055496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisone
Description: Day 1:~Rituximab at 375 mg/m2 Cyclophosphamide at 375 mg/m2 (cohort 1), 550mg/m2 (cohort 2), 750 mg/m2 (cohort 3, 4) Vincristine at 1.4 mg/m2 (max 2 mg)~Day 2 Inotuzumab ozogamicin at 0.8 mg/m2 (cohort 1, 2, 3), 1.3 mg/m2 (cohort 4)~Days 1-5:~Prednisone at 40 mg/m2~Each cycle is 3 weeks, with a maximum of 6 cycles total.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inotuzumab ozogamicin+rituximab+gemcitabine+cisplatinum+dexamethasone
Description: Day 1:~Rituximab at 375 mg/m2 Gemcitabine at 500 mg/m2 (cohort 1, 2b, 3b), 1000mg/m2 (cohort 2a, 3a, 4, 5) Cisplatin at 37.5 mg/m2 (cohort 1, 2a), 50mg/m2 (cohort 2b, 3a), 75mg/m2 (cohort 3b, 4, 5)~Day 2:~Inotuzumab ozogamicin at 0.8 mg/m2 (cohort 1, 2a, 2b, 3a, 3b, 4), 1.3mg/m2 (cohort 5)~Days 1-4:~Dexamethasone at 40 mg~Each cycle is 3 weeks, with a maximum of 6 cycles total.
Study: NCT04688879

Intervention type: PROCEDURE
Intervention: intra-arterial urokinase thrombolysis
Description: Under local anaesthesia, the right femoral artery was punctured in accordance with the Seldinger technique, and a 6-Fr sheath, 10 cm in length, was implanted. Selective catheterization of the SMA was performed with 4-Fr catheter. The SMA angiography was performed to identify the filling defect. Thrombolysis was performed using a 5-Fr multiple-sideport infusion catheter (100cm with sideport of 7cm, 14 ports or 100cm with sideport of 15cm, 30 ports, Cook, Bloomington, IN, U.S.A). The tip of the microcatheter was embedded in the thromboembolism, which was fragmented at the time of thrombolysis. Thrombolysis was performed locally in the SMA with a bolus of urokinase
Study: NCT02240147

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: home-based exercise training
Description: During a 30 minute face-to-face motivational interview with an exercise specialist, the patient will be advised and coached about his exercise prescription, on how to implement it in his own daily life and on how to prevent relapse. Furthermore, the patients will receive instructions on how to monitor their exercise intensity and on recognizing adverse signals. During the following 12 weeks, patients will be asked to exercise 4.5 hours per week within the prescribed exercise intensity range according to the guidelines.
Study: NCT00597337

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FearNot
Description: Behavioral: Three sessions of FearNot!v.2.0 software interaction over a three-week period (each session lasting approximately 30 minutes)
Study: NCT03446261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvamibe® Tab
Description: Rosuvastatin 5mg/ezetimibe 10mg qd for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monorova® Tab
Description: Rosuvastatin 10mg qd for 8 weeks
Study: NCT01007682

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Show distressing movie and tell half of the two study groups to suppress memories of the movie
Description: A distressing movie is presented to two groups (one group with high and one group with low working memory capacity). For each of the two groups, half of the participants are instructed to suppress thoughts of the movies after viewing it, while the remaining participants are instructed to allow the occurrence of memories of the movie.
Study: NCT04195737

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ossix volumax collagen matrix
Description: Under LA horizontal incision is made.Split-full-split thickness flap is elevated.The remaining soft tissue of the anatomic interdental papillae deepithelialized.Coronal advancement of the flap obtained and closed using sling suture.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Connective Tissue Graft
Description: Under LA parallel incisions is made 1-2 mm first molar to canine.Graft incision 1 mm coronal to the horizontal flap incision.Through this incision designed graft thickness is obtained.The graft obtained between the two horizontal incisions has a 1 mm coronal strip that require depithelisation with a knife and closed using interrupted suture.
Study: NCT01754909

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: Enalapril once a day, orally, as 2.5 , 5, or 10 mg tablets to be given in escalating doses, to subjects undergoing radiotherapy for lung cancer

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo, once a day, orally, as 2.5 , 5, or 10 mg tablets to be given in escalating doses, to subjects undergoing radiotherapy for lung cancer
Study: NCT02853227

Intervention type: OTHER
Intervention: digital photography
Description: Photographies with digital cameras were taken postoperatively for the documentation, anonymised and used for evaluation of cosmetic results after surgery.

Intervention type: OTHER
Intervention: digital photography
Description: Photographies with digital cameras were taken postoperatively for the documentation, anonymised and used for evaluation of cosmetic results after surgery.
Study: NCT04073303

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A
Description: Day 1 Administration of bilateral intramuscular injections into the masseter
Study: NCT02533674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus PM060184
Study: NCT04778709

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Puros allograft
Description: Bilateral sinus augmentation procedure using the lateral window technique. Graft material combination A or B will be randomly assigned to right and left sinus.~Each subject will receive the following bone allograft material:~Four to six grams of commercially available human donor bone allograft (Puros Allograft Bone Particles, Zimmer Biomet, Palm Beach Gardens, FL USA) consisting of Graft A cortical and cancellous bone chips of both 250-1000 microns and 1000-2000 microns size, or Graft B for contralateral sinus: cancellous 1000-2000 microns size alone.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Puros allograft
Description: Bilateral sinus augmentation procedure using the lateral window technique. Graft material combination A or B will be randomly assigned to right and left sinus.~Each subject will receive the following bone allograft material:~Four to six grams of commercially available human donor bone allograft (Puros Allograft Bone Particles, Zimmer Biomet, Palm Beach Gardens, FL USA) consisting of Graft A cortical and cancellous bone chips of both 250-1000 microns and 1000-2000 microns size, or Graft B for contralateral sinus: cancellous 1000-2000 microns size alone.
Study: NCT04315207

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone call
Description: All patients are informed that they will receive a telephone call between 08 AM and 5 PM on workdays, as soon as the results of invasive workup are available. This is expectedly 3 to 5 days after invasive workup. At the telephone call, patients are free to ask for a later call, to summon relatives, to turn on the loud speaker, and/or ask the physician to call one relative of choice to share the information.~Regardless of group, all patients are informed on the possibility of malignancy at every patient-physician encounter.
Study: NCT02178436

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04315207

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-person meeting
Description: All patients are provided a written and verbal appointment date 5 workdays after invasive workup, and that they will receive a telephone call if 1) results are not available at the time of the meeting, and/or 2) if results need urgent action (such as small-cell lung cancer).~At the in-person meeting, patients are free to invite family and relatives (up to 4 persons, restriction due to space available).~Regardless of group, all patients are informed on the possibility of malignancy at every patient-physician encounter.
Study: NCT01579305

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Juvéderm® Volbella with Lidocaine
Description: Up to 4.0 mL at the discretion of the Investigator to achieve optimal results
Study: NCT02178436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Given IV
Study: NCT01579305

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane-L®
Description: Up to 4.0 mL at the discretion of the Investigator to achieve optimal results
Study: NCT01894360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab 200 mg/mL
Description: Clear to opalescent, colorless to pale yellow sterile solution sterile solution for SC injection in a single-use liquid formulation of Belimumab 200 mg/mL will be supplied in 1mL long glass prefilled syringe or autoinjector device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab 200 mg/mL
Description: Clear to opalescent, colorless to pale yellow sterile solution sterile solution for SC injection in a single-use liquid formulation of Belimumab 200 mg/mL will be supplied in 1mL long glass prefilled syringe or autoinjector device.
Study: NCT04341350

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol + analgesic drug
Description: sedation according to a written, standardized Nurse management protocol using at least one sedative drug (propofol) and one analgesic drug. It uses the nurse driven analgesia protocol of each ward involved in the study. It uses a pain assessment score (BPS, VICOMORE, FLACC), local or regional anesthesia, non-opioïd adjuncts (acetaminophen, NSAIDs, nefopam), opioïds (per os opioïds, bolus of sufentanyl followed by continuous infusion if necessary, continuous infusion of remifentanyl
Study: NCT01820104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lansoprazole, 30 mg per day for 6 days
Study: NCT04341350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflurane + analgesic drug
Description: sedation by inhalation of halogenated gas (Isoflurane) delivered by the Anesthetic-Conserving Device (ACD) system ANACONDA ™ associated with the administration of a analgesic drug. It uses the nurse driven analgesia protocol of each ward involved in the study. It uses a pain assessment score (BPS, VICOMORE, FLACC), local or regional anesthesia, non-opioïd adjuncts (acetaminophen, NSAIDs, nefopam), opioïds (per os opioïds, bolus of sufentanyl followed by continuous infusion if necessary, continuous infusion of remifentanyl.
Study: NCT03911193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Patients will be treated with cabozantinib 60 mg/daily (cycles each 28 days) until progression, toxicity or patient refusal.
Study: NCT01377311

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transplant of cultured limbal stem cells on cornea
Description: Remove the abnormal surface tissue on the lesion cornea, transplant the amniotic membrane with cultured limbal stem cells on the denuded cornea. Cover with contact lens after operation, and apply topical antibiotics and steroids.
Study: NCT03203707

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal and Social Rhythm Therapy
Description: The Brief IPSRT intervention for at-risk youth includes : 1) Psychoeducation about risk for BP ; 2) Social rhythm therapy (SRT) aiming to establish and maintain stable routines to protect against onset of mood symptoms in vulnerable individuals ; and 3) Interpersonal Psychotherapy (IPT) centering on the adolescent's feelings about having a parent with BP, and linking stressful family events to mood. The intervention is delivered in 8 in-person sessions over 6 months of treatment. Parents are involved in the psychoeducation sessions, and further involvement is determined as clinically appropriate based on age and developmental status.
Study: NCT00576394

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Insulin drip
Description: IV insulin drip at 100units insulin in 100ml saline designed to keep blood glucose between 120-180mg/dl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: IV insulin drip to keep serum glucose between 80-120mg/dl.
Study: NCT00553111

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational video
Description: educational video
Study: NCT00732459

Intervention type: DEVICE
Intervention: Electro-acupuncture preconditioning
Description: electro-acupuncture
Study: NCT03391154

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levothyroxin
Description: 90 female received levothroxine
Study: NCT01835561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Single oral dose of 4-mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 4-mg capsule
Study: NCT01686204

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low fat dairy yogurt
Description: Consumption of 12 oz of low fat dairy yogurt daily for 9 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low fat dairy yogurt
Description: Consumption of 12 oz of low fat dairy yogurt daily for 9 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Soy pudding
Description: Consumption of 12 oz of low fat soy pudding daily for 9 weeks.
Study: NCT04334681

Intervention type: PROCEDURE
Intervention: Un-roofing curettage method
Description: In this method, the roof of the pilonidal cyst is opened, and the inside is cleaned, and curettage is performed. The wound is closed with a dressing after hemostasis.

Intervention type: PROCEDURE
Intervention: Modified Limberg Flap Group
Description: In this method, the pilonidal cyst is excised with a rhomboid incision and closed with the modified Limberg flap method.
Study: NCT03882372

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal high flow
Description: See arm description.
Study: NCT01033370

Intervention type: DRUG
Group type: OTHER
Intervention: clevidipine.
Description: Clevidipine administered per IV infusion, starting dose of 2 mg/h (4 mL/hr) for 3 minutes \& titrated to the desired BP lowering effect to SBP goal of \< 120 mmHg, max infusion rate may not exceed 32 mg/h (64 mL/hr).
Study: NCT01229111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib maleate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study: NCT01686204

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soy pudding
Description: Consumption of 12 oz of low fat soy pudding daily for 9 weeks.
Study: NCT01815437

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mushroom Vitamin D2
Description: 2000 IU vitamin D2 in a mushroom extract, once/day for 12 weeks
Study: NCT03623490

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: managment of oral therapy
Description: Initial consultation with a trio oncologist / pharmacist / nurse
Study: NCT01210599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamidronate
Description: The study was a randomized, double blind, dose-escalation trial of IV pamidronate. Study participants were divided among four study phases. Each group received IV placebo or escalating doses of IV pamidronate of 30mg, 60mg, 90mg and 180mg.
Study: NCT03609944

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERCP with miES
Description: Endoscopic retrograde cholangiopancreatography with minor papilla endoscopic sphincterotomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS
Description: Endoscopic ultrasound

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: EUS
Description: Endoscopic ultrasound
Study: NCT01749293

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Haploidentical Transplant
Description: Subjects will be dosed with pre-transplant Fludarabine (180mg/m2)and Busulfan total AUC 2400 μmol\*min/L or 6.4mg/kg. Subjects will then undergo total body irradiation 2Gy. Subjects will undergo haploidentical allogeneic bone marrow transplant, followed by Cyclophosphamide, Tacrolimus and MMF based GVHD prophylaxis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Subjects in this trial will receive Fludarabine 30 mg/m2 IV QD, adjusted for CrCl from Days -8 through -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Subjects in this trial will receive Busulfan total AUC 2400 μmol\*min/L or 6.4mg/kg in 4 doses with seizure prophylaxis from Days -6 through -3.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Subjects in this trial will receive total body irradiation (2Gy fractionated) from Day -2 or -1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Subjects in this trial will receive Cyclophosphamide 50 mg/kg IV QD on Days 3 and 4 post-transplant.
Study: NCT02250573

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Replenine®-VF (High Purity Factor IX)
Study: NCT04302168

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Choline supplement
Description: Choline 470mg twice daily for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill twice daily for 8 weeks
Study: NCT04370847

Intervention type: PROCEDURE
Intervention: Spinal Anesthesia
Description: Performed at the L3-L4 or L4-L5 interspace using a 25-gauge spinal needle

Intervention type: DRUG
Intervention: Intrathecal Bupivacaine
Description: Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
Study: NCT01815437

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: 2000 IU crystalline cholecalciferol once/day for 12 weeks
Study: NCT04370847

Intervention type: DRUG
Intervention: Intrathecal Fentanyl
Description: Fentanyl 15 μg will be administered in the subarachnoid space

Intervention type: PROCEDURE
Intervention: Cesarean Delivery
Description: Lower segment cesarean section using the Pfannenstiel incision